Press release
Abiomed's Impella(R) Technology Showcased at TCT 2015 With Over 25 Presentations in the Scientific Sessions
DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announces that there are currently over 25 presentations potentially featuring the Impella line of heart pumps, scheduled in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific meeting, scheduled from October 11 - 15, at the Moscone Convention Center in San Francisco.
On the TCT show floor, at Abiomed's booth #1117 there will be daily demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform with new simulator technology.
Additionally, Abiomed anticipates the broadcast of potentially multiple live cases utilizing Impella from the participating live case sites in the main arena, coronary theater and structural heart theater in the Moscone Center. Further details concerning these live cases will be disclosed the day of the scheduled procedures, as patient status is subject to change.
The schedule for Protected PCI or CHIP (Complex Higher-Risk and Indicated Patients) related TCT symposiums is below. There are additional Impella-related presentations and poster sessions anticipated at TCT. For a full list of anticipated presentations and further information about Abiomed at TCT 2015, please contact Aimee Genzler, Director, Corporate Communications, at [email protected] or 978-646-1553
MONDAY, OCTOBER 12, 2015
TCT BREAKFAST SESSION —Treatment of Complex Higher-Risk Patients: Introduction to Protected PCI (Sponsored by the Cardiovascular Research Foundation)
Moscone Center
Room 122
| 6:30 — 8:00 a.m. |
| Speakers: |
| John M. Lasala, MD, PhD |
| George Vetrovec, MD |
| Jeffrey Moses, MD |
| William Lombardi, MD |
TUESDAY, OCTOBER 13, 2015
Complex and High-Risk Intervention (CHIP): TCT 20: Use of a Percutaneous Left Ventricular Assist Device for High-Risk Percutaneous Coronary Interventions — Clinical Trial Versus Real-World Experience
CVAD Registry Results
Moscone Center
Room Moscone West, 2nd Floor, Room 2012
| 2:30 p.m. |
| Speaker: |
| Mauricio G. Cohen, MD |
TCT Symposium: Evening Program: The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP) (Sponsored by the Cardiovascular Research Foundation)
Grand Ballroom A
Hilton San Francisco Union Square
| 6:00 — 8:00 p.m. |
| Speakers: |
| Jeffrey Moses, MD |
| Ajay Kirtane, MD |
| J. Grantham, MD |
| Dimitri Karmpaliotis, MD |
| Philippe Généreux, MD |
WEDNESDAY, OCTOBER 14, 2015
TCT BREAKFAST SESSION - Management of Complex PCI Patients: Award-Winning Case Presentations
Moscone Convention Center
Room 121
| 6:30 — 8:00 a.m. |
| Speakers: |
| George Dangas, MD |
| Theodore Schreiber, MD |
| George Vetrovec, MD |
Complex PCI Case-Based Review: SCAI Women in Innovations (WIN)
Moscone Center
Presentation Theater - Presentation 1
| 11:30 — 12:30 p.m. |
| Moderator: |
| Cindy Grines, MD |
| Discussants: |
| Amir Kaki, MD |
| Roxana Mehran, MD |
| Ruby Satpathy, MD |
| Kim Skelding, MD |
| Paul Teirstein, MD |
CHIP: Calcified Lesions, Multivessel/Diffuse Disease, Vein Grafts, Shock, and More
Moscone West, 2nd Floor,
Room 2001 - 2005
2:00 pm - 6:00 pm
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.